AbbVie Inc (ABBV)vsAuna S.A. (AUNA)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
AUNA
Auna S.A.
$5.07
-0.78%
HEALTHCARE · Cap: $375.47M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1295% more annual revenue ($61.16B vs $4.39B). ABBV leads profitability with a 6.9% profit margin vs 2.2%. AUNA trades at a lower P/E of 13.7x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
AUNA
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Intrinsic value data unavailable for AUNA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Reasonable price relative to book value
Attractively priced relative to earnings
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 6.5% — below average capital efficiency
2.2% margin — thin
Earnings declined 50.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : AUNA
The strongest argument for AUNA centers on Price/Book, P/E Ratio.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : AUNA
The primary concerns for AUNA are Market Cap, Return on Equity, Profit Margin. Debt-to-equity of 2.23 is elevated, increasing financial risk. Thin 2.2% margins leave little buffer for downturns.
Key Dynamics to Monitor
AUNA carries more volatility with a beta of 1.64 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 48/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Auna S.A.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Auna S.A. is a prominent telecommunications and digital services provider in Latin America, specializing in integrated solutions that enhance connectivity and customer experience. With a comprehensive portfolio that includes high-speed internet, television, and mobile services, Auna caters to both residential and business clients across a variety of markets. The company's dedication to innovation and exceptional customer service has established it as a key player in the region's dynamic digital landscape. Its extensive and robust infrastructure positions Auna favorably to leverage the growing demand for advanced telecom solutions, presenting significant growth opportunities for institutional investors.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?